Results 111 to 120 of about 27,689 (240)
Frontiers in OncologyBackgroundRichter transformation refers to the progression of an initially slow-growing small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) into an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma ...
Annaïse J. Jauch +8 more
doaj +1 more source
Health Science Reports, Volume 9, Issue 7, July 2026.ABSTRACT Background and Aims Multidrug resistance (MDR) is a major determinant of relapse‐associated mortality in pediatric acute lymphoblastic leukemia (pALL). Although miR‐326 downregulation has been associated with poor prognosis, its role in chemoresistance remains undefined. This study investigated the mechanistic contribution of miR‐326 to MDR in
Narges Aberuyi +2 more
wiley +1 more source
Haematologica, 2014 The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial.
Wyndham H. Wilson +19 more
doaj +1 more source
Reconceptualizing Aplastic Anemia—Seed, Worm, Soil
Journal of Clinical Laboratory Analysis, Volume 40, Issue 14, July 2026.Aplastic anemia (AA) encompasses a group of hematological syndromes often misdiagnosed, resulting in a decrease in the overall blood cell count and representing a form of bone marrow failure. We reinterpret AA based on the “seed, worm, and soil” doctrine.
Xintong Xu +4 more
wiley +1 more source
Inverse Argyll Robertson pupil in Burkitt′s lymphoma [PDF]
, 2008 Kakarla V Chalam, Shailesh K Gupta, Vikram S BrarDepartment of Ophthalmology, University of Florida Health Science Center, Jacksonville, FL, USAAbstract: We present a case of an 18 year old white male with Burkitt’s lymphoma who was operated on
Kakarla V Chalam +2 more
core
The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen +9 more
wiley +1 more source
Journal of Inherited Metabolic Disease, Volume 49, Issue 4, July 2026.ABSTRACT Propionic acidemia (PA) is a rare inherited metabolic disorder associated with recurrent metabolic decompensations and chronic multisystemic complications. Liver transplantation (LT) may improve metabolic stability, but its long‐term impact on organ involvement remains debated.
Tristan Mekdade +25 more
wiley +1 more source
Burkitt lymphoma affecting the right heart. A case from practice [PDF]
, 2017 Berkitt lymphoma as a primary malignant tumor of the heart occurs extremely rarely. By the time of the diagnosis, patients already have regional or distant metastases, which greatly worsens their clinical condition and the prognosis of surgical treatment.
O.A. Pishchurin +4 more
core
Medicinal Research Reviews, Volume 46, Issue 4, Page 989-1004, July 2026.ABSTRACT CRISPR‐Cas9 genome‐wide screening has been instrumental towards identifying novel targets for drug discovery in cancer research. However, much of this research has centred specifically on adult cancers, with paediatric cancers being underserviced by current research and screening.
Steven He +2 more
wiley +1 more source
British Journal of Haematology, Volume 209, Issue 1, Page 116-126, July 2026.Summary Therapeutic options for relapsed or refractory diffuse large B‐cell lymphoma (rDLBCL) have expanded following accelerated approvals based largely on surrogate end‐points, yet confirmatory studies have not consistently reproduced these benefits across all agents, and outcomes for many patients remain poor.
Elizabeth Goodall +11 more
wiley +1 more source